SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-078840
Filing Date
2022-07-11
Accepted
2022-07-11 16:53:13
Documents
4
Period of Report
2022-08-11

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2219814-2_def14a.htm DEF 14A 1634524
2 GRAPHIC lg_nabriva-4c.jpg GRAPHIC 80041
3 GRAPHIC tm2219814d1-px_page02bw.jpg GRAPHIC 647932
4 GRAPHIC tm2219814d2-px_page01bw.jpg GRAPHIC 1099492
  Complete submission text file 0001104659-22-078840.txt   4150966
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37558 | Film No.: 221077405
SIC: 2834 Pharmaceutical Preparations